Related Experiment Video
Updated: Sep 28, 2025
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
8.8K
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
Miguel García-Pardo1, Maisam Makarem1, Janice J N Li1
1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
British Journal of Cancer
|March 29, 2022
Summary
Circulating tumor DNA (ctDNA) analysis revolutionizes solid tumor management through liquid biopsies. This review explores ctDNA
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Precision medicine advances rely on identifying genomic alterations in solid tumors.
- Liquid biopsy, using circulating tumor DNA (ctDNA), is now integral for molecular profiling.
Purpose of the Study:
- To review the clinical applications of ctDNA in solid tumors, focusing on non-small cell lung cancer.
- To highlight ctDNA's role as a biomarker for prognostication, treatment monitoring, and early diagnosis.
Main Methods:
- Review of current literature on ctDNA detection and characterization.
- Analysis of clinical utility and emerging applications of liquid biopsies.
Main Results:
- ctDNA enables non-invasive molecular profiling for targeted therapies.
- ctDNA serves as a sensitive biomarker for minimal residual disease detection and recurrence surveillance.
Conclusions:
- ctDNA analysis is transforming patient management in oncology.
- Future applications of ctDNA in early diagnosis and comprehensive disease monitoring are promising.
